These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 15558447

  • 1. [Consensus-recommendations for sirolimus in liver transplantation].
    Golling M, Becker T, Broelsch C, Candinas D, Faust D, Fischer L, Geissler E, Graeb C, Iberer F, Klupp J, Kraus T, Müller AR, Neuhaus P, Strassburg CP, Wolff M, Zülke C, Bechstein WO.
    Z Gastroenterol; 2004 Nov; 42(11):1333-40. PubMed ID: 15558447
    [Abstract] [Full Text] [Related]

  • 2. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 3. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.
    Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC.
    Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus as rescue therapy after liver transplantation.
    Reigada CH, de Ataide EC, de Araújo FR, Ramos AP, Stucchi RS, Eescanhoela CA, Boin IF.
    Transplant Proc; 2012 Oct; 44(8):2434-7. PubMed ID: 23026613
    [Abstract] [Full Text] [Related]

  • 5. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS, Ramicone E, Fong TL.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):513-20. PubMed ID: 16441472
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus for solid organ transplantation in children.
    Gupta P, Kaufman S, Fishbein TM.
    Pediatr Transplant; 2005 Jun 15; 9(3):269-76. PubMed ID: 15910380
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus: new preparation. No tangible advance in renal transplantation.
    Prescrire Int; 2002 Dec 15; 11(62):165-6. PubMed ID: 12469693
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus for rescue of steroid and anti-thymocyte globulin-resistant recurrent acute rejection after liver transplantation: report of one case.
    Demirağ A, Kalayci M, Ekci B, Gülçelik T, Gökçe O.
    Transplant Proc; 2009 Dec 15; 41(1):435-6. PubMed ID: 19249574
    [Abstract] [Full Text] [Related]

  • 9. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.
    Transplantation; 2007 May 15; 83(9):1162-8. PubMed ID: 17496530
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 15; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA, Heizer KE.
    Nephrol Nurs J; 2000 Dec 15; 27(6):623-5. PubMed ID: 16649344
    [Abstract] [Full Text] [Related]

  • 12. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul 15; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Jul 15; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 15; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus in renal transplantation.
    Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
    Nephrol Dial Transplant; 2007 Sep 15; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
    Jensen GS, Wiseman A, Trotter JF.
    Liver Transpl; 2008 May 15; 14(5):601-3. PubMed ID: 18433068
    [No Abstract] [Full Text] [Related]

  • 19. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC, Warshaw BL.
    Pediatr Transplant; 2005 Aug 15; 9(4):520-2. PubMed ID: 16048606
    [Abstract] [Full Text] [Related]

  • 20. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient.
    Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z, Cyganek A, Pawlowska J, Teisseyre M, Kalicinski P, Markiewicz M, Paczek L, Socha J.
    Transplant Proc; 2004 Dec 15; 36(10):3232-3. PubMed ID: 15686735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.